Last synced from Twitter Not synced yet
Hedge Funds’ Shot at Keeping Stock Investments Secret Fades
U.S. regulators are shelving a controversial plan to allow most hedge funds to keep their stock investments secret.
1
Michelle Solly
Retailers rejoice! The 13F thresholds are staying the same
“U.S. regulators are shelving a controversial plan to allow most hedge funds to keep their stock investments secret”
126d
ACTIV-3 Statement 2 Title
Eli Lilly and Company
1
Michelle Solly
$LLY Here’s the PR
“Based on an updated dataset from the trial reviewed on October 26, no additional COVID-19 patients in this hospitalized setting will receive bamlanivimab...bamlanivimab is unlikely to help hospitalized COVID-19 patients recover”
126d
Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
1
Michelle Solly
$CATB Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
PolarisDMD Trial Did Not Achieve Primary or Secondary Endpoints
127d
Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium
Preliminary Clinical Activity and Safety Profile Support Advancing to Dose Expansion in Multiple Tumor Types Recommended Phase 2 Dose Determination...
1
Michelle Solly
$TPTX Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium
129d
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies
-50% (2/4) complete response (CR) rate at three months in the Dose Level 3 (DL3) cohort; both responders remain in CR- -Early evidence of dose-dependent...
1
Michelle Solly
$CRSP CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies
132d
Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency
Vertex today provided an update on its clinical programs targeting the small molecule correction of alpha-1 antitrypsin deficiency (AATD).
1
Michelle Solly
$VRTX Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency
- Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data
139d
Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
SAN CARLOS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T...
1
Michelle Solly
$IOVA Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
Delayed BLA
148d
Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical...
2
Michelle Solly
$YMAB Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma
Receives RTF
148d
BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement
BridgeBio to Acquire All Outstanding Shares of Eidos it Does Not Already Own Agreement Brings BridgeBio’s Clinical Development and Commercial...
Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Patients with Advanced Systemic Mastocytosis
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...
1
Michelle Solly
$BPMC Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Patients with Advanced Systemic Mastocytosis
ORR 75%
161d
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
Early cancer detection could identify tumors when outcomes are superior at a time
when outcomes are superior and treatment is less morbid. This prospective case-control
sub-study (from NCT02889978 and NCT03085888) assessed the performance of...
2
Michelle Solly
$GRAL GRAIL files for IPO. Developing a multi-cancer early detection blood test
$ILMN spinout
GRAIL has raised over $1.8B in private funding
Cancers detected with 99.3% specificity, with varying degree across stages: annalsofoncology.org/article/S0923-…
S-1: sec.gov/Archives/edgar…
174d
Document
2
Michelle Solly
$GRAL GRAIL files for IPO. Developing a multi-cancer early detection blood test
$ILMN spinout
GRAIL has raised over $1.8B in private funding
Cancers detected with 99.3% specificity, with varying degree across stages: annalsofoncology.org/article/S0923-…
S-1: sec.gov/Archives/edgar…
174d
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
– Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody – – Gilead to Make $85 Million Upfront Payment and $35 Million...
1
Michelle Solly
$JNCE $GILD Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
182d
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered...
1
Michelle Solly
$IONS $AKCA Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash
183d
Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis
Company to Host Conference Call on August 25, 2020 at 8:30am EDT
1
Michelle Solly
$IMVT Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis
189d
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and...
2
Michelle Solly
$MORF $ABBV Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
189d
Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update
ROS1+ TKI-Naïve Non-Small Cell Lung Cancer Confirmed Objective Response Rate is 86 Percent ROS1+ TKI-Pretreated Non-Small Cell Lung Cancer with One Prior...
1
Michelle Solly
$TPTX Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update
195d
Editas Medicine Regains Full Global Rights to Ocular Medicines
Enhances strategic flexibility and control of lead programs, including EDIT-101
1
Michelle Solly
$EDIT $ABBV $EDIT $AGN Editas Medicine Regains Full Global Rights to Ocular Medicines
Including lead program EDIT-101
208d
Genocea to Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine GEN-009 in Combination with Checkpoint Inhibitors | Genocea Biosciences
1
Michelle Solly
$GNCA Three of five patients achieved separate RECIST responses after GEN-009 administration
215d
Live
2:00 PM EST Press Briefing with Press Secretary Sarah Sanders 4:15 PM EST Vice President Pence Delivers Remarks at an America First Policies Event